Orakl Oncology raises $34M
Orakl Oncology announced a Series A round of $34M on 12 November 2026. The company operates in HealthTech and is based in France. It was founded by Fanny Jaulin, CEO. Announced yesterday.
Founder
Fanny Jaulin
CEO, Orakl Oncology
LinkedIn not available
Outreach angles
- -Fanny Jaulin has led Orakl Oncology as CEO, steering a €3M first raise in 2023 and an €11M round in 2024.
- -Under Jaulin, Orakl built a collection of tumour avatars to help biopharma predict how drug candidates will perform on patients.
- -Orakl Oncology raised a $34M Series A to scale its AI-powered virtual cancer patients for testing drugs before clinical trials.
Signals
Series ADeep TechHealthcareAI-Native
Round details
Company: Orakl Oncology
Domain: orakl oncology
Amount: $34M
Stage: Series A
Industry: HealthTech
Country: France
Announced: 12 November 2026
Other HealthTech raises
Recently funded in France